Jade Biosciences Inc (JBIO) FinancialsJBIOJade Biosciences Inc

Evaluating the bottom line, Jade Biosciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -38.80%, provide a clear picture of how effectively JBIO converts its operational activities into shareholder value.

In the context of the broader market, JBIO competes directly with industry leaders such as ODTX and KURA. With a market capitalization of $936.79M, it holds a leading position in the sector. When comparing efficiency, JBIO's gross margin of N/A stands against ODTX's N/A and KURA's 98.84%. Such benchmarking helps identify whether Jade Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

Jade Biosciences reported a net loss of $55.76 million for Q2 2026, with an EPS of -0.76, indicating ongoing financial challenges. The company has high R&D expenses, which surged to $50.06 million, reflecting its commitment to drug development but also straining its finances.